Best Life Sciences Companies in Haidian, China
The 34 best Life Sciences companies in Haidian, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: LinkDoc.
Our analysis of 50 Life Sciences companies
$5.7b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Haidian
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | LinkDoc 🦄 Provider of the oncology-focused database 76Moat top 15%AI top 20%Market top 25%Product top 26% All 10 signals ▾Moattop 15% AItop 20% Markettop 25% Producttop 26% Innovationtop 27% Fundingtop 31% Talentbottom 49% Globalbottom 38% Newsbottom 27% Techbottom 24% Moat: Editorial + unicorn rating 9/10 · Unicorn AI: Classified as an AI company rank vs industry peers · Fliar Intelligence Index 76/100 | $263M | 67 mo ago | Series D | Tony Zhang Founder & CEO | 1,250 | — | — |
| 2 | StoneWise Provider of a software solution solution for molecular modeling | $100M | 66 mo ago | Series B | Zhou Jielong Founder & CEO | — | — | — |
| 3 | Huaxia Yingtai Biotechnology Developer of CAR-T cell therapies for treating cancer | $38M | 60 mo ago | Series B | Lin Xin Founder | — | — | — |
| 4 | Beijing Haosi Biotechnology Provider of services in analytical testing using mass spectroscopy | $31M | 64 mo ago | Series B | Li Lin Founder & CEO | — | — | — |
| 5 | BEIJING X-MAGTECH TECHNOLOGIES Developer of non-invasive magnetic resonance imaging equipment 64Funding top 32%Market top 39%Talent bottom 45%Global bottom 36% All 4 signals ▾Fundingtop 32% Markettop 39% Talentbottom 45% Globalbottom 36% Funding: Raised $28.7M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Market: 150 employees (top 24% of HealthTech) rank vs industry peers · Fliar Intelligence Index 64/100 | $29M | 27 mo ago | Series A | Bin Cai Founder & CEO | 150 | — | — |
| 6 | Beijing Rubber Xin Biological Technology Developer of tumor genetic testing reagents and instruments | $29M | 46 mo ago | Series B | Cao Shanbai CEO | — | — | — |
| 7 | Beijing Zhongyin Technology Digital clinical genetic diagnosis tool for providers 42Funding top 41%Talent bottom 45%Global bottom 29% All 3 signals ▾Fundingtop 41% Talentbottom 45% Globalbottom 29% Funding: Raised $26.5M · 3 rounds over 5 yrs (0.6/yr) Talent: 1 named leader on record rank vs industry peers · Fliar Intelligence Index 42/100 | $26M | 36 mo ago | Series A | Zhong Xiancheng CEO | — | — | — |
| 8 | Beijing Xinyi Biotechnology Manufacturer of micro-droplet digital PCR and in vitro diagnostic reagents | $23M | 32 mo ago | Series B | Wenjun Yang Co-Founder | — | — | — |
| 9 | Danyang Huichuang Medical Equipment Provider of infrared spectroscopy brain function imaging solutions | $17M | 35 mo ago | Series B | Wang Daifa Founder | 13 | — | — |
| 10 | Hocermed Manufacturer of medical devices | $15M | 71 mo ago | Series C | — | 20 | — | — |
| 11 | Beijing Youxun Medical Laboratory Provider of tests for detecting non-invasive single gene disorders, prenatal testing and tumor detection | $15M | 53 mo ago | Series B | Ye Zhou CEO | — | — | — |
| 12 | Aojing Medical Technology Manufacturer of regenerative medicine materials and implantable medical devices | $6M | 92 mo ago | Series A | — | 114 | — | — |
| 13 | Beijing Vision Technology Provider of wearable EEG devices for brainwave biofeedback | $3M | 96 mo ago | Seed | Zhang Bohan founder | — | 295 patents Advanced video processing, playback speed control, watermarking, and special effects technologies | — |
| 14 | Gongyingshi B2B procurement platform for R&D labs | $2M | 117 mo ago | Series B | — | 50 | — | — |
| 15 | Beijing Yifei Huatong Technology Development Engaged in brain science research, development, and clinical transformation application | $2M | 105 mo ago | Seed | Wu Yibing Founder | — | — | — |
Top 12 Life Sciences companies in Haidian
#1
Series A · Haidian, Beijing · founded 2020 · 150 employees$28.7Mraised▾
Developer of non-invasive magnetic resonance imaging equipment. The company offers a liquid-free helium magnetocardiography that detects the weak magnetic field for large-scale cardiovascular functional imaging.
- Jul 2024Series A$13.8M
- Jun 2022Series A$15M
#2
Series B · Haidian, Beijing · founded 2015$23.2Mraised▾
Beijing Xinyi Biotechnology is manufacturing micro-droplet digital PCR and in vitro diagnostic reagents. Products include drop maker sample preparation, chip reader, PCR universal amplification reagent, genetic testing kit (for scientific research only), micro-droplet detection oil, nucleic acid extraction reagent (magnetic beads method), etc.
- Feb 2024Series B—
- Jan 2021Series B$23.2M
- Sep 2018Seed—
#3
Series A · Haidian, Beijing · founded 2015$26.5Mraised▾
Developer of clinical genetic diagnosis, fertility prevention and gene therapy drug for hereditary eye diseases. The company specializes in developing ophthalmic gene therapy drugs backed by accurate gene diagnosis, providing reliable ophthalmic gene pharmaceuticals for the public.
#4
Series B · Haidian, Beijing · founded 2016 · 13 employees$16.6Mraised▾
Provider of infrared spectroscopy brain function imaging solutions. The system is meant for neuroscience, psychology, physiology, human function, rehabilitation, and mental illness. The solutions are portable and come with data analysis software for the analysis of results.
- Oct 2023Series B$13.7M
- Jun 2022Series A—
- Jul 2021Series A—
- Sep 2020Series A$1.5M
#5
LinkDoc 🦄Series D · Haidian, Beijing · founded 2014 · 1250 employees$263.3Mraised▾
Provider of the oncology-focused database. It is a big data company that is involved in medical information systems integration and application software development. It claims to have built a rich repository of cancer patients' medical records and comprehensive clinical data. It empowers evidence-based, personalized cancer treatment in China by providing doctors with valuable analytics derived from its oncology database.
- Mar 2021Series D—
- Sep 2020Series D$102.3M
- Jul 2018Series D$151M
- Apr 2016Series B—
#6
Series B · Haidian, Beijing · founded 2017$28.7Mraised▾
Developer of tumor genetic testing reagents and instruments. It has developed AcornSTAS for solid tumor mutations, AcornHMAS for hematological tumor mutations, AcornSTDB which is a solid tumor gene knowledge database and others.
- Dec 2022Series B$28.7M
- Apr 2020Series A—
#7
Series B · Haidian, Beijing · founded 2018$100Mraised▾
Stonewise provides a software solution for molecular modeling. It uses artificial intelligence-based technology for molecule design. It also gives the software for synthetic product prediction and drug knowledge mining.
- Apr 2021Series B$100M
- Sep 2020Series A—
- Mar 2020Series A—
- 2018Seed—
#8
Series B · Haidian, Beijing · founded 2018$37.5Mraised▾
Developer of CAR-T cell therapies for treating cancer. The company has T cell transformation technology platforms, STAR-T and TCR-T, and has built a mature industrialization platform for process development and quality control. It is developing pipeline of products for treatment of hematological tumors and other indfectious diseases.
- Oct 2021Series B$31M
- Jan 2020Series A$6.5M
#9
Series B · Haidian, Beijing · founded 2016$31.3Mraised▾
Beijing Haosi Biotechnology offers services in analytical testing using mass spectroscopy. The company has developed clinical mass spectrometry screening products, including Alzheimer's disease, cardiovascular disease, and urinary diseases. It also helps in the screening of genetic metabolic diseases, drug concentration testing, metabolite testing (amino acids, fatty acids, bile acids), steroid testing, and more
- Jun 2021Series B$31.3M
- Dec 2020Series B—
#10
Series B · Haidian, Beijing · founded 2014$14.9Mraised▾
Provider of tests for detecting non-invasive single gene disorders, prenatal testing, and tumor detection. The services include hereditary tumor susceptibility gene screening, tumor personalized treatment gene detection, circulating tumor DNA (ct DNA) detection, circulating tumor cells (CTC ) assessment, and monitoring.
- May 2022Series B—
- Jul 2017Series A—
#11
Series C · Haidian, Beijing · founded 2010 · 20 employees$15.1Mraised▾
Provider of ultrasound surgical products and related services. The company's products are mainly based on the application of ultrasonic technology including high-efficiency ultrasonic transducer, multi-mode power ultrasonic technology, enabling the surgeons to reduce the difficulty to perform precision operations and reduce the pain of patients at the same time.
- Nov 2020Series C$15.1M
#12
Series A · Haidian, Beijing · founded 2004 · 114 employees$5.7Mraised▾
Manufacturer of regenerative medicine materials and implantable medical devices
- Jan 2019Series A—
- Jul 2013Series A$5.7M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in China
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 5,865 China-affiliated papers.
- Chinese Academy of Sciences263
- Chinese Academy of Agricultural Sciences227
- Ministry of Agriculture and Rural Affairs168
- China Agricultural University159
- Huazhong Agricultural University138
- Gene4→218
- Gene knockdown3→73
- Transcriptome1→62
- Detection limit1→59
- Mutant3→56
- Gene9→275
- Gene knockdown1→166
- Downregulation and upregulation2→161
- Apoptosis6→129
- Transcription factor3→77
- Agriculture6→68
- Antibiotic resistance1→43
- Resistance (ecology)2→33
- Gene2→32
- Synthetic biology1→30
Where biotechnology is researched across China
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in China
China biotechnology patent filing is accelerating — 58,925 filings from 8,000 assignees (2016–2025), led by Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine, UNIV Jiangnan; annual filings 1737→10545.
- Shanghai Hengrui Pharmaceutical1154
- Jiangsu Hengrui Medicine1027
- UNIV Jiangnan1000
- Innovent Biologics Suzhou666
- UNIV Tsinghua627
- Jiangsu Hengrui Pharmaceuticals594
- UNIV Xiamen575
- UNIV Beijing549
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.